Professional
Added to YB: 2025-05-07
Pitch date: 2025-03-31
GKOS [neutral]
Glaukos Corporation
-3.25%
current return
Author Info
No bio for this author
Company Info
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Market Cap
$5.2B
Pitch Price
$98.06
Price Target
N/A
Dividend
N/A
Sector
Health Care Equipment and Supplies
Category
turnaround
Baron Health Care Fund Portfolio Holding: Glaukos Corporation
GKOS (holding update): Glaukos shares fell on iDose missing high expectations. Doctors hesitant until reimbursement confirmed - Medicare coverage starting to solidify. Uptake should accelerate as process streamlines. iDose delivers prostaglandin inside eye for up to 3 years. Glaucoma market ripe for intervention, potential $1B product.
Read full article (1 min)